Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zim Laboratories's Enterprise Value is ₹5,950 Mil.
Zim Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹306 Mil. Therefore, Zim Laboratories's EV-to-EBIT ratio for today is 19.47.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Zim Laboratories's Enterprise Value is ₹5,950 Mil.
Zim Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹465 Mil. Therefore, Zim Laboratories's EV-to-EBITDA ratio for today is 12.79.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Zim Laboratories's Enterprise Value is ₹5,950 Mil.
Zim Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹3,674 Mil. Therefore, Zim Laboratories's EV-to-Revenue ratio for today is 1.62.
Zim Laboratories Enterprise Value Historical Data
The historical data trend for Zim Laboratories's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zim Laboratories's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's Enterprise Value falls into.
Zim Laboratories Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Zim Laboratories's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (BOM:541400) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Zim Laboratories's current Enterprise Value is ₹5,950 Mil.
Zim Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹306 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Zim Laboratories's current Enterprise Value is ₹5,950 Mil.
Zim Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹465 Mil.
Zim Laboratories's current Enterprise Value is ₹5,950 Mil.
Zim Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,674 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories Enterprise Value Related Terms
Thank you for viewing the detailed overview of Zim Laboratories's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Zim Laboratories (BOM:541400) Business Description
Zim Laboratories Ltd is a pharmaceutical company. It is mainly engaged in the manufacturing of formulation drugs and pre-formulation ingredients. Geographically, the group has a business presence in India and other countries, of which key revenue is derived from Outside India. The products offered by the company are Ondansetron, Tadalafil, Vitamin D3, Levocetirizine, Methylcobalamin, and others. The majority of its revenue gets derived from the sale of pharmaceutical goods.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:541400 has been successfully added to your 